World Stroke Day - SVIN latest clinical trials and breaking science news

The Society of Vascular and Interventional Neurology (SVIN) would like to announce today on World Stroke Day that it stands committed to the advancement of scientific research to improve the lives of stroke (aka brain-attack) patients worldwide. Stroke and interventional neurologists, who are members of the SVIN, working collaboratively with interventional neuro-radiologists and endovascular neurosurgeons have played a pivotal role in clinical trials pioneering the use of clot retrieval devices, such as retrievable stents and vacuum aspiration devices, also referred to as stroke thrombectomy.

"This collaborative effort, with stroke surgeons worldwide, has led to the establishment of stroke thrombectomy as a standard of care for large vessel occlusion (LVO) stroke." explains Italo Linfante, MD FAHA FSVIN, current President of the SVIN. "We are at a very exciting phase in brain-attack care similar to heart-attack care in the mid-90's. The results of the latest clinical trials and breaking news on next-generation devices that can transform stroke thrombectomy in the next decade, will be among the key highlights at our upcoming annual meeting." summarizes Dr. Linfante.

In the past year, there have been two randomized clinical trials (ASTER and COMPASS) evaluating the role of vacuum aspiration for removing blood clots in LVO stroke patients. In addition, there have been two randomized clinical trials evaluating the role of stroke thrombectomy in extended treatment time windows (DAWN: within 6-24 hours and DEFUSE 3: within 6-16 hours of stroke onset) to benefit LVO stroke patients including those who wake up with a stroke.

"We are pleased to announce that the results of another landmark clinical trial for stroke thrombectomy, namely the POSITIVE Stroke Clinical Trial will be presented at the upcoming SVIN annual meeting." reiterates Ameer E. Hassan, DO FAHA FSVIN, Chair of SVIN's 2018 annual meeting. Lead authors Drs. J Mocco and Aquilla Turk, along with their POSITIVE trial collaborators will be presenting the results of the POSITIVE (PerfusiOn Imaging Selection of Ischemic STroke PatIents for EndoVascular ThErapy) Stroke Clinical Trial (ClinicalTrials.gov NCT01852201). This is a randomized clinical trial comparing endovascular treatment (stroke thrombectomy with vacuum aspiration or a retrievable stent, separately or in combination) versus best medical therapy in LVO stroke patients with appropriate imaging selection within 6-12 hours of stroke onset.

A panel of leading stroke experts rigorously reviewed over 150 scientific research submissions to select the latest clinical trials and breakthrough technology to be showcased at the SVIN's 2018 annual meeting. Thanh Nguyen, MD FRCPc FAHA FSVIN, Chair of SVIN's scientific research committee explains, "In addition to the latest clinical trials, we want to showcase the groundbreaking science behind the most innovative devices that have tremendous potential to improve stroke thrombectomy worldwide."

One such news is from lead authors Drs. Miklos Marosfoi and Matthew J. Gounis, who along with their collaborators at the University of Massachusetts, will be presenting foundational research on a new aspiration device platform that can offer cyclical vacuum aspiration (varying the vacuum suction intensity) as a means of improving clot ingestion into aspiration catheters. In addition, they will be presenting the role of cyclical vacuum aspiration in decreasing release of dangerous debris during stroke thrombectomy that could cause secondary stroke.

The SVIN 2018 Annual Meeting will be held November 14-17 in San Diego, California. "We are excited that stroke surgeons, clinical trialists, and innovators worldwide are choosing the SVIN annual meeting forum to present the results of the latest clinical trials and breaking news on next-generation technologies that can have a transformative impact on stroke thrombectomy and thereby improving the lives of stroke patients and their caregivers worldwide." concludes Dr. Linfante.

About SVIN

The Society of Vascular and Interventional Neurology was created to achieve the highest level of care for patients through increased collaboration in scientific research and by educating young professionals and training young investigators. The Society also aims to provide opportunities to connect leaders in the field and provide a common ground for dialogue and creation of practice and safety standards. Our mission is to represent the advancement of interventional neurology as a field with the ultimate goal of improving clinical care and outcomes of patients with stroke and cerebrovascular diseases.

The SVIN Annual Meeting is a premier academic venue with scientific presentations covering the full spectrum of cerebrovascular diseases and stroke. Participants have the opportunity to discuss embolectomy, aneurysms and AVMs, subarachnoid and intracranial hemorrhage, endovascular saves and innovative approaches, new device review, international perspectives, and other-related topics. The SVIN 2018 Annual Meeting will be held November 14-17 in San Diego, California. New for 2018, SVIN is pleased to announce a vascular neurology track, an advance practice provider track, a live Basic Stroke Emergency Support course, and a hands on fellows training course. Registration for the SVIN 2018 Annual Meeting is now open.

For further information about SVIN, please visit http://www.svin.org

Most Popular Now

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...